<DOC>
<DOCNO>EP-0613465</DOCNO> 
<TEXT>
<INVENTION-TITLE>
1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K314439	A61K3144	A61K314402	A61P4300	A61P1300	C07D29503	A61K31357	A61K31506	C07D21170	A61K31425	A61P1500	A61K31496	A61K3144	A61P1500	A61P2500	A61K31425	A61K314433	A61K31496	C07D40108	A61P2500	C07D21338	C07D40904	A61K31444	C07D21100	A61K314436	A61P2518	C07D29500	C07D23942	A61P1302	A61K31357	C07D31758	C07D40508	A61K31506	A61K314402	A61K314427	C07D21182	C07D40100	C07D21374	C07D41708	A61P4300	C07D31700	C07D29502	A61K31495	A61K314965	A61K31497	A61K31443	A61P2516	C07D21300	C07D40500	A61P900	C07D40900	C07D41700	A61P2514	A61K314427	C07D23900	A61K31495	A61K3136	C07D23926	A61P912	C07D40908	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61P	A61P	C07D	A61K	A61K	C07D	A61K	A61P	A61K	A61K	A61P	A61P	A61K	A61K	A61K	C07D	A61P	C07D	C07D	A61K	C07D	A61K	A61P	C07D	C07D	A61P	A61K	C07D	C07D	A61K	A61K	A61K	C07D	C07D	C07D	C07D	A61P	C07D	C07D	A61K	A61K	A61K	A61K	A61P	C07D	C07D	A61P	C07D	C07D	A61P	A61K	C07D	A61K	A61K	C07D	A61P	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61P43	A61P13	C07D295	A61K31	A61K31	C07D211	A61K31	A61P15	A61K31	A61K31	A61P15	A61P25	A61K31	A61K31	A61K31	C07D401	A61P25	C07D213	C07D409	A61K31	C07D211	A61K31	A61P25	C07D295	C07D239	A61P13	A61K31	C07D317	C07D405	A61K31	A61K31	A61K31	C07D211	C07D401	C07D213	C07D417	A61P43	C07D317	C07D295	A61K31	A61K31	A61K31	A61K31	A61P25	C07D213	C07D405	A61P9	C07D409	C07D417	A61P25	A61K31	C07D239	A61K31	A61K31	C07D239	A61P9	C07D409	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
The present invention relates to novel
substituted 1,3-cycloalkenes and cycloalkanes useful
as pharmaceutical agents, to methods for their
production, to pharmaceutical compositions which
include these compounds and a pharmaceutically
acceptable carrier, and to their use for the manufacture of
pharmaceutical compositions e.g. for the treatment of psychoses.
The novel compounds of the present invention are central nervous
system agents. More particularly, the novel compounds of the present
invention are dopaminergic agents.A series of substituted cyclohexenes represented
by the Formula I

wherein
R1 is aryl, 2-, 3-, or 4-pyridinyl or 2-, 3-or
4-pyridinyl substituted by lower alkyl, lower
alkoxy, or halogen, 2-, 4-, or 5-pyrimidinyl or
2-, 4-, or 5-pyrimidinyl substituted by lower
alkyl, lower alkoxy, or halogen, 2-pyrazinyl or
2-pyrazinyl substituted by lower alkyl, lower
alkoxy, or halogen, 2- or 3-thienyl or 2- or
3-thienyl substituted by lower alkyl or halogen,
2- or 3-furanyl or 2- or 3-furanyl substituted by
lower alkyl or halogen, 2-, 4-, or 5-thiazolyl or
2-, 4-, or 5-thiazolyl substituted by lower alkyl
or halogen; m is zero or an integer from one to two;
R2 is
wherein R1 is as defined above;
n is zero or an integer from one to four; and
corresponding optical isomers thereof; or a
pharmaceutically acceptable acid addition salt
thereof, useful as dopaminergic agents, is disclosed
in United States Patent 4,975,445.A series of 1-indolylalkyl-4-substituted
pyridinyl piperazines represented by Formula I
R1, R2 is H or 1-4C alkyl;R3, R4, R8, R9 is H, lower alkyl, lower alkoxy,
carbamide, halo, CF3, or thio-lower alkyl;
provided that R8 and R9 are not both H;A is 5-7C cycloalkyl or cycloalkenyl, or
- (CH2)n-CHR5-;n is 1, 2, or 3;R5 is R1;R6, R7 is H or Me; orR4 + R7 is a methylene. bridge or a pharmaceutically
acceptable acid addition salt useful in the treatment
of depression, anxiety, and panic disorders is
disclosed in European Patent Application EP-345,808A.However, the compounds disclosed in the
aforementioned references do not disclose or suggest 
the combination of structural variations of the
compounds of the present invention described
hereinafter.Accordingly, the present invention is a compound
of Formula I
Z-CH2-Ywherein Z is
wherein R is a phenyl group unsubstituted or
substituted by one to four substituents selected
from C1-C6 alkyl, C1-C6 alkoxy, C1-C6 thioalkoxy,
hydroxy, halogen, trifluoromethyl, amino, C1-C6
alkylamino or di- C1-C6 alkylamino or 1,3-benzodioxol-5-yl,
2-, 3-, or
</DESCRIPTION>
<CLAIMS>
A compound of Formula I

Z-CH
2
-Y
wherein Z is

wherein R is a phenyl group unsubstituted or
substituted by one to four substituents selected

from C
1
-C
6
 alkyl, C
1
-C
6
 alkoxy, C
1
-C
6
 thioalkoxy,
hydroxy, halogen, trifluoromethyl, amino, C
1
-C
6

alkylamino or di- C
1
-C
6
 alkylamino or 1,3-benzodioxol-5-yl,
2-, 3-, or 4-pyridinyl or

2-, 3-, or 4-pyridinyl substituted by C
1
-C
6

alkyl, C
1
-C
6
 alkoxy, hydroxy, or halogen, 2-,
4-
, or 5-pyrimidinyl or 2-, 4-, or
5-pyrimidinyl substituted by C
1
-C
6
 alkyl,
C
1
-C
6
 alkoxy, hydroxy, or halogen,
2-pyrazinyl or 2-pyrazinyl substituted by

C
1
-C
6
 alkyl, C
1
-C
6
 alkoxy, hydroxy, or
halogen, 2- or 3-thienyl or 2- or 3-thienyl

substituted by C
1
-C
6
 alkyl or halogen, 2- or
3-furanyl or 2- or 3-furanyl substituted by

C
1
-C
6
 alkyl or halogen, 2-, 4-, or
5-thiazolyl, or 2-, 4-, or 5-thiazolyl

substituted by lower alkyl or halogen,
3-indolyl, 2-, 3-, or 4-quinolinyl, and
m is an integer of 1, 2, or 3,


wherein R and m are as defined
above, 



wherein R and m are as defined
above, or



wherein R is as defined above;
Y is


wherein R is as defined above or


wherein R is as defined above; and
corresponding isomers thereof; or a

pharmaceutically acceptable acid
addition salt thereof.
A compound according to Claim 1, in which

R is phenyl, phenyl substituted by C
1
-C
6
 alkyl,
C
1
-C
6
 alkoxy, C
1
-C
6
 dialkoxy, halogen,
hydroxy, dihydroxy, amino, C
1
-C
6
 alkyl amino,
C
1
-C
6
 dialkyl amino, 2- or 3-pyridyl, 2- or
3-pyridyl substituted by C
1
-C
6
 alkyl, C
1
-C
6

alkoxy, or halogen, 2- or 3-thienyl, 2- or
3-thienyl substituted by C
1
-C
6
 alkyl, C
1
-C
6

alkoxy, or halogen, 2-, 3- or 5-pyrimidinyl,
2-, 3-, or 4-quinolinyl, 3-indolyl, or


m is an integer of 1 or 2; and Y is


wherein R is as defined above.
A compound according to Claim 2, in which

R is phenyl, phenyl substituted by para-halogen,

para
-methoxy, 
ortho
 or 
para
 C
1
-C
6
 alkyl, 
para

mono- or di-C
1
-C
6
 alkyl amino, 2- or
3-pyridyl, 2- or 3-thienyl, 5-pyrimidinyl,

3-quinolinyl, 3-indolyl or

m is an integer of 2; and Y is


wherein R is as defined above.
A compound according to Claim 3 selected from the
group consisting of:


(±)-1,2,3,6-Tetrahydro-4-phenyl-1-[(3-phenyl-3-cyclohexen-1-yl)methyl]pyridine;
(±)-1,2,3,6-Tetrahydro-4-phenyl-1-[(3-phenyl-2-cyclohexen-1-yl)methyl]pyridine;
(±)-1,2,3,6-Tetrahydro-4-phenyl-1-[[3-(2-thienyl)-3-cyclohexen-1-yl]methyl]
pyridine;
(±)-1,2,3,6-Tetrahydro-4-phenyl-1-[[3-(2-thienyl)-2-cyclchexen-1-yl]methyl]
pyridine;
(±)-1-[[3-(4-Fluorophenyl)-3-cyclohexen-1-yl]methyl]
-1,2,3,6-tetrahydro-4-phenylpyridine;
(±)-1-[[3-(4-Fluorophenyl)-2-cyclohexen-1-yl]methyl-1,2,3,6-tetrahydro-4-phenylpyridine;
(+)-1,2,3,6-Tetrahydro-4-phenyl-1-[(3-phenyl-3-cyclohexen-1-yl)methyl]pyridine;
(-)-1,2,3,6-Tetrahydro-4-phenyl-1-[(3-phenyl-3-cyclohexen-1-yl)methyl]pyridine;
(R)-1-[[3-(4-chlorophenyl)-3-cyclohexen-1-yl]methyl]
-1,2,3,6-tetrahydro-4-phenylpyridine; 
(R)-1-[[3-(4-chlorophenyl)-2-cyclohexen-1-yl]methyl]
-1,2,3,6-tetrahydro-4-phenylpyridine;
(R)-1-[[3-(4-fluorophenyl)-3-cyclohexen-1-yl]methyl]
-1,2,3,6-tetrahydro-4-phenylpyridine;
(R)-1,2,3,6-tetrahydro-1-[[3-(4-methylphenyl)-3-cyclohexen-1-yl]methyl]
-4-phenylpyridine;
(R)-1,2,3,6-tetrahydro-4-phenyl-1-[[3-(2-thienyl)-3-cyclohexen-1-yl]methyl]
pyridine
monohydrochloride;
(R)-1,2,3,6-tetrahydro-4-phenyl-1-[[3-(2-thienyl)-2-cyclohexen-1-yl]methyl]
pyridine
monohydrochloride;
(R) -1,2,3,6-tetrahydro-1- [[3- (4-methoxyphenyl)-3-cyclohexen-1-yl]methyl]
-4-phenylpyridine
monohydrochloride;
(R)-3-[5-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-1-cyclohexen-1-yl]
pyridine
monohydrochloride;
(R)-3-[3-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-1-cyclohexen-1-yl]
pyridine
dihydrochloride;
(R)-1,2,3,6-tetrahydro-1-[[3-(2-methylphenyl)
-2-cyclohexen-1-yl]
methyl] -4-phenylpyridine;
(R)-1,2,3,6-tetrahydro-1-[[3-(2-methylphenyl)-3-cyclohexen-1-yl]methyl]
-4-phenylpyridine;
(R)-5-[5-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-1-cyclohexen-1-yl]
pyrimidine
monohydrochloride;
(R)-5-[3-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-1-cyclohexen-1-yl]
pyrimidine
dihydrochloride;
(R)-1,2,3,6-tetrahydro-4-phenyl-1-[[3-(3-thienyl)-2-cyclohexen-1-yl]methyl]
pyridine; 
(R)-4-[5-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-1-cyclohexen-1-yl]
-N,N-dimethylbenzeneamine;
(R)-4-[3-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-1-cyclohexen-1-yl]
-N,N-dimethylbenzeneamine;
(R)-3-[5-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-1-cyclohexen-1-yl]
-quinoline;
(R)-3-[3-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]
-1-cyclohexen-1-yl]
 -quinoline;
(R)-1-[[3-(1,3-benzodioxol-5-yl)-3-cyclohexen-1-yl]methyl]
-1,2,3,6-tetrahydro-4-phenylpyridine
monohydrochloride;
(1S-cis)-N-[3-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]cyclohexyl]
benzamide;
(1R-Cis)-1,2,3,6-tetrahydro-4-phenyl-1-[(3-phenylcyclohexyl)methyl]pyridine

monohydrochloride;
(1R-Trans)-1,2,3,6-tetrahydro-4-phenyl-1-[(3-phenylcyclohexyl)methyl]pyridine

monohydrochloride;
(±)-1,2,3,6-tetrahydro-1-[(3-phenyl-3-cyclohexen-1-yl)methyl]-4-(2-thienyl)pyridine

monohydrochloride; and
(±)-3-[5-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-1-cyclohexen-1-yl]
-1H-indole.
A compound according to claim 3 having the name (+)-1,2,3,6-Tetrahydro-4-phenyl-1-
[(3-phenyl-3-cyclohexen-1-yl)methyl]
pyridine.
A compound according to Claim 1, in which

R is phenyl, phenyl substituted by C
1
-C
6
 alkyl,
C
1
-C
6
 alkoxy, C
1
-C
6
 dialkoxy, halogen,
hydroxy, dihydroxy, amino, C
1
-C
6
 alkyl amino,
C
1
-C
6
 dialkyl amino, 2- or 3-pyridyl, 2- or
3-pyridyl substituted by C
1
-C
6
 alkyl, C
1
-C
6
 
C
1
-C
6
 alkoxy, or halogen, 2- or 3-thienyl, 2-or
3-thienyl substituted by C
1
-C
6
 alkyl,
C
1
-C
6
 alkoxy, or halogen, 2-, 3- or
5-pyrimidinyl, 2-, 3- or 4-quinolinyl,

3-indolyl, or

m is an integer of 1 or 2; and Y is


wherein R is as defined above.
A compound according to Claim 6, in which

R is phenyl, phenyl substituted by 
para
-halogen,

para
-methoxy, 
ortho
 or 
para
 C
1
-C
6
 alkyl, 
para

mono- or di-C
1
-C
6
 alkyl amino, 2- or
3-pyridyl, 2- or 3-thienyl, 5-pyrimidinyl,

3-quinolinyl, 3-indolyl or

m is an integer of 2; and Y is


wherein R is as defined above.
A compound according to Claim 7 selected from the
group consisting of:


(±)-1-[(3-Phenyl-3-cyclohexen-1-yl)methyl] -4-(2-pyridinyl)piperazine;
(±)-1-[(3-Phenyl-2-cyclohexen-1-yl)methyl]-4-(2-pyridinyl)piperazine;
(±)-1-[[3-(4-Fluorophenyl)-3-cyclohexen-1-yl]methyl]
-4-(2-pyridinyl)piperazine;
(±)-1-[[3-(4-Fluorophenyl)-2-cyclohexen-1-yl]methyl]
-4-(2-pyridinyl)piperazine; 
(R)-1-[(3-Phenyl-3-cyclohexen-1-yl)methyl]-4-(2-pyridinyl)piperazine;
(±)-1-Phenyl-4-[(3-phenyl-3-cyclohexen-1-yl)methyl]piperazine

dihydrochloride;
(±)-2-[4-[[3-phenyl-3-cyclohexen-1-yl)methyl]-1-piperazinyl]
pyrimidine;
and
(±)-1-[(3-phenyl-3-cyclopenten-1-yl)methyl]-4-(2-pyridinyl)piperazine.
Use of a compound according to anyone of claims 1
to 8 for the manufacture of a pharmaceutical

composition for treating psychoses, hypertension,
galactorrhea, amenorrhea, menstrual disorders,

sexual dysfunction, Parkinson's disease, or
Huntington's chorea comprising administering in a

host suffering therefrom.
Use of a compound according to anyone of claims 1
to 8 for the manufacture of a pharmaceutical

composition for treating schizophrenia in a host
suffering therefrom.
Use of a compound according to anyone of claims 1
to 8 for the manufacture of a pharmaceutical

composition as a dopaminergic, antipsychotic, or
antihypertensive agent.
A pharmaceutical composition comprising a
compound according to any one of claims 1 to 8

and a pharmaceutically acceptable excipient
diluent or carrier.
A method of preparing a compound having the
Formula Ia


Z
a
-CH
2
-Y
wherein Z
a
 is


wherein R is a phenyl group unsubstituted or
substituted by one to four substituents selected

from C
1
-C
6
 alkyl, C
1
-C
6
 alkoxy, C
1
-C
6
 thioalkoxy,
hydroxy, halogen, trifluoromethyl, amino, C
1
-C
6

alkylamino or di- C
1
-C
6
 alkylamino or 1,3-benzodioxol-5-yl,
2-, 3-, or 4-pyridinyl or 2-,

3-, or 4-pyridinyl substituted by C
1
-C
6

alkyl, C
1
-C
6
 alkoxy, hydroxy, or halogen, 2-,
4-, or 5-pyrimidinyl or 2-, 4-, or

5-pyrimidinyl substituted by C
1
-C
6
 alkyl,
C
1
-C
6
 alkoxy, hydroxy, or halogen,
2-pyrazinyl or 2-pyrazinyl substituted by

C
1
-C
6
 alkyl, C
1
-C
6
 alkoxy, hydroxy, or
halogen, 2-, or 3-thienyl or 2- or 3-thienyl

substituted by C
1
-C
6
 alkyl or halogen, 2- or
3-furanyl or 2- or 3-furanyl substituted by

C
1
-C
6
 alkyl or halogen, 2-, 4-, or
5-thiazolyl, or 2-, 4-, or 5-thiazolyl

substituted by C
1
-C
6
 alkyl or halogen,
3-indolyl, 2-, 3-, or 4-quinolinyl, and m is

an integer of 1, 2, or 3, and

wherein R and m are as defined above;
Y is

wherein R is as defined above or

wherein R is as defined above; and corresponding 
isomers thereof; or a pharmaceutically

acceptable acid addition salt thereof
comprises reacting a compound of Formula II


wherein m and Y are as defined above with a
compound of Formula III


R-M
wherein M is Mg Hal wherein Hal is halogen or Li
in a solvent followed by reaction with an acid in

a solvent to afford a compound of Formula Ia and,
if desired, converting a compound of Formula Ia to

a corresponding pharmaceutically acceptable acid
addition salt by conventional means and, if so

desired, converting the corresponding
pharmaceutically acceptable acid addition salt to

a compound of Formula Ia by conventional means.
A method of preparing a compound having the
Formula Ib


Z
b
-CH
2
-Y
a
wherein Z
b
 is


wherein R is a phenyl group unsubstituted or
substituted by one to four substituents selected

from C
1
-C
6
 alkyl, C
1
-C
6
 alkoxy, C
1
-C
6
 thioalkoxy,
hydroxy, halogen, trifluoromethyl, amino, C
1
-C
6

alkylamino or di- C
1
-C
6
 alkylamino or 1,3-benzodioxol-5-yl,
2-, 3-, or 4-pyridinyl or 2-,

3-, or 4-pyridinyl substituted by C
1
-C
6

alkyl, C
1
-C
6
 alkoxy, hydroxy, or halogen, 2-,
4-, or 5-pyrimidinyl or 2-, 4-, or 

5-pyrimidinyl substituted by C
1
-C
6
 alkyl,
C
1
-C
6
 alkoxy, hydroxy, or halogen,
2-pyrazinyl or 2-pyrazinyl substituted by

C
1
-C
6
 alkyl, C
1
-C
6
 alkoxy, hydroxy, or
halogen, 2-, or 3-thienyl or 2- or 3-thienyl

substituted by C
1
-C
6
 alkyl or halogen, 2- or
3-furanyl or 2- or 3-furanyl substituted by

C
1
-C
6
 alkyl or halogen, 2-, 4-, or
5-thiazolyl, or 2-, 4-, or 5-thiazolyl

substituted by C
1
-C
6
 alkyl or halogen,
3-indolyl, 2-, 3-, or 4-quinolinyl, and m is

an integer of 1, 2, or 3, and
Y
a
 is


wherein R is as defined above; and corresponding
isomers thereof; or 
a pharmaceutically acceptable
acid addition salt thereof comprises reacting a

compound of Formula Ic

Z
a
-CH
2
-Y
a

wherein Z
a
 and Y
a
 are as defined above with
hydrogen in the presence of a catalyst in a

solvent to afford a compound of Formula Ib and, if
desired, converting a compound of Formula Ib to a

corresponding pharmaceutically acceptable acid
addition salt by conventional means and, if so

desired, converting the corresponding
pharmaceutically acceptable acid addition salt to

a compound of Formula Ib by conventional means.
A method of preparing a compound having the
Formula Id


Z
b
-CH
2
-Y
wherein Z
b
 is

wherein R is a phenyl group unsubstituted or
substituted by one to four substituents selected

from C
1
-C
6
 alkyl, C
1
-C
6
 alkoxy, C
1
-C
6
 thioalkoxy,
hydroxy, halogen, trifluoromethyl, amino, C
1
-C
6

alkylamino or di- C
1
-C
6
 alkylamino or 1,3-benzodioxol-5-yl,
2-, 3-, or 4-pyridinyl or 2-,

3-,or 4-pyridinyl substituted by C
1
-C
6
 alkyl,
C
1
-C
6
 alkoxy, hydroxy, or halogen, 2-, 4-, or
5-pyrimidinyl or 2-, 4-, or 5-pyrimidinyl

substituted by C
1
-C
6
 alkyl, C
1
-C
6
 alkoxy,
hydroxy, or halogen, 2-pyrazinyl or

2-pyrazinyl substituted by C
1
-C
6
 alkyl, C
1
-C
6

alkoxy, hydroxy, or halogen, 2-, or 3-thienyl
or 2- or 3-thienyl substituted by C
1
-C
6
 alkyl
or halogen, 2- or 3-furanyl or 2- or

3-furanyl substituted by C
1
-C
6
 alkyl or
halogen, 2-, 4-, or 5-thiazolyl, or 2-, 4-,

or 5-thiazolyl substituted by C
1
-C
6
 alkyl or
halogen, 3-indolyl, 2-, 3-, or 4-qinolinyl,

and m is an integer of 1, 2, or 3,
Y is

wherein R is as defined above or

wherein R is as defined above;
and corresponding isomers thereof; or a

pharmaceutically acceptable acid addition salt
thereof comprises reacting a compound of

Formula IV 

wherein R, m, and Y are as defined above with a
reducing reagent to afford a compound of

Formula Id and, if desired converting a compound
of Formula Id to a corresponding pharmaceutically

acceptable acid addition salt by conventional
means and, if so desired, converting the

corresponding pharmaceutically acceptable acid
addition salt to a compound of Formula Id by

conventional means.
</CLAIMS>
</TEXT>
</DOC>
